Development code · Small Molecule
ALKS-33
ALKS-33 is a development code for LYBALVI (olanzapine/samidorphan), developed by Alkermes plc.
- Status
- Phase 3 for Schizophrenia
- Mechanism
- D2 Antagonist
- Developer
- Alkermes plc
Programs
- LYBALVI (olanzapine/samidorphan) for SchizophreniaPhase 3Recruiting
Also known as
- LYBALVI
- ALKS 3831
- OLZ/SAM
- olanzapine/samidorphan
- olanzapine and samidorphan
- olanzapine
- 132539-06-1
- samidorphan
- 852626-89-2